Vitamin D Supplementation in Intensive Care Unit Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

340 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-20

Study Completion Date

2019-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized controlled trial is designed to investigate the safety and clinical efficacy of a mega dose of VD in patients admitted in intensive care unit (ICU). Patients will be randomly allocated to receive 400,000 IU of VD3 or placebo. They will be followed up until ICU discharge or death or the 15th day of ICU stay. Adverse events that occur during ICU stay is collected. Primary outcome is intensive care unit-acquired infection (ICU-AI), and secondary outcomes are septic shock, organ failure, and ICU-mortality. Plasma 25-hydroxyvitamin D is assessed at baseline and at the end of follow-up. Cox regression models will be applied to test how VD supplementation affects adverse outcomes while adjusting for confounders.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Vitamin D3 Supplementation for Critically Ill Patients

NCT05937789

Vitamin D Deficiency Critical Illness

RECRUITING NA

Vitamin D to Improve Outcomes by Leveraging Early Treatment

NCT03096314

Acute Respiratory Distress Syndrome Vitamin D Deficiency Critical Illness

COMPLETED PHASE3

Effects of Enteral Supplement Vitamin D Incritically Ill Patients

NCT04292873

Vitamin D Deficiency Critical Illness

COMPLETED NA

Cholecalciferol Supplementation in Critically Ill Patients With Severe Vitamin D Deficiency.

NCT02868827

Vitamin D Deficiency Critical Illness

TERMINATED PHASE2/PHASE3

Dietary Supplementation With 25-hydroxyvitamin D3 in Older Adults

NCT01398202

Vitamin D Status as Reflected by Serum 25-hydroxyvitamin D

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The randomized controlled trial aimed to investigate the safety and clinical efficacy of a single mega dose of vitamin D (VD) in patients admitted at intensive care unit (ICU).

Study participants: VD deficient ICU patients

Criteria of inclusion, patients:

* newly admitted (within 24 hours)
* over eighteen,
* able to receive medication orally or through nasogastric tube
* expected to stay more than 72 hours in ICU.

Criteria for non-inclusion and exclusion, patients:

* lack of patient's or relatives' consent
* expected short life or ICU stay (\<48 hours)
* sepsis at admission
* kidney, liver or intestinal disease
* hypercalcemia (total calcium\>10.6 mg/dL)
* history of a disorder associated with hypercalcemia (cancer, tuberculosis, sarcoidosis, hyperparathyroidism, nephrolithiasis)
* treatment with immunotherapy or vitamin supplements within one year
* pregnant or breastfeeding women
* discharge from ICU or death within 72 hours of admission

Study protocol

Patients will undergo physical examination with calculation of acute physiology and chronic assessment II (APACHE II) and sequential organ failure assessment (SOFA) scores. They will be randomly assigned to either VD or placebo group after stratification on gender, age and APACHE II:

* VD group, 170 patients will receive a single dose of 400,000 IU of VD3 orally or through nasogastric tube
* Placebo group, 170 patients will receive distilled water orally or through nasogastric tube.

The patients will followed up until ICU discharge or death or the 15th day of ICU stay, whichever occurs first and adverse events that occurred during ICU stay were collected.

Primary outcome: intensive care unit-acquired infection (ICU-AI), defined as an infection of blood stream, lower respiratory tract, urinary tract, skin/soft tissue or gastrointestinal tract, which was not present within the first 48 hours of admission into the ICU.

Secondary outcomes: urinary calcium:creatinine ratio as surrogate for VD toxicity, septic shock, organ failure, ICU-mortality.

Plasma 25-hydroxyvitamin D (25-OHD) will be assessed at baseline and the end of follow-up using immunoassay.

Cox regression models will be applied to test how VD supplementation affects adverse events and ICU-mortality while adjusting for confounders.

Hypothesis. Recovering an adequate VD status might reduce poor outcome, especially infectious outcomes in ICU patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dietary Supplements Intensive Care Unit Vitamin D Deficiency Vitamin D Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vitamin D group

170 patients receiving a single dose of 400,000 IU of VD3 (2 vials of 200,000 IU VD3; B.O.N., BOUCHARA RECORDATI) orally or through a nasogastric tube

Group Type EXPERIMENTAL

Vitamin D supplementation

Intervention Type DIETARY_SUPPLEMENT

Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements

Placebo group

170 patients receiving distilled water (2 vials of 1 ml distilled water) orally or through a nasogastric tube

Group Type SHAM_COMPARATOR

Vitamin D supplementation

Intervention Type DIETARY_SUPPLEMENT

Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D supplementation

Patients are randomized to receive vitamin D or placebo and followed up for 15 days at maximum to investigate the safety and clinical efficacy of the supplements

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* newly admitted (within 24 hours)
* over eighteen,
* able to receive medication orally or through nasogastric tube
* expected to stay more than 72 hours in ICU
* given consent

Exclusion Criteria

* lack of patient's or relatives' consent
* expected short life or ICU stay (\<48 hours)
* sepsis at admission
* kidney, liver or intestinal disease
* hypercalcemia (total calcium\>10.6 mg/dL)
* history of a disorder associated with hypercalcemia (i.e., cancer, tuberculosis, sarcoidosis, hyperparathyroidism, nephrolithiasis)
* treatment with immunotherapy or vitamin supplements within one year
* pregnant or breastfeeding women
* discharge from ICU or death within 72 hours of admission

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No